

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023

Tricia Lee Rolle, Senior Advisor, ONC

June 15, 2023





Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Roster

Name	Organization	Name	Organization
Shelly Spiro (Co-Chair)	Pharmacy HIT Collaborative	Hans Buitendijk* (Co-Chair)	Oracle Health
Pooja Babbrah	Point-of-Care Partners	Ketan Mehta	Micro Merchant Systems
Chris Blackley	Prescryptive	Justin Neal	Noble Health Services
Shila Blend*	North Dakota Health Information Network	Eliel Oliveira*	Dell Medical School, University of Texas at Austin
David Butler	Curatro	Scott Robertson	Bear Health Tech Consulting
Rajesh Godavarthi*	MCG Health, part of the Hearst Health network	Alexis Snyder*	Individual
Adi V. Gundlapalli**	Centers for Disease Control and Prevention	Fillipe Southerland*	Yardi Systems, Inc.
Jim Jirjis*	HCA Healthcare	Naresh Sundar Rajan*	CyncHealth
Summerpal Kahlon	Rocket Health Care	Christian Tadrus	Community Pharmacy Owner
Steve Lane*	Health Gorilla	Sheryl Turney*	Elevance Health
Anna McCollister*	Individual	Afton Wagner	Walgreens
Deven McGraw*	Invitae Corporation		

* HITAC Member ** HITAC Federal Representative

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge

Overarching charge: Identify recommendations to support interoperability between pharmacy constituents, and the exchange of information necessary for medication management, patient safety and consumer engagement.

Recommendations Due: November 9, 2023

Specific charge:

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities

Short-term

3

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

Long-term

a. Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.

Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 Charge (Continued)

Specific charge:

- 2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.
 - a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
 - b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
 - c. What technology gaps exist for pharmacists to participate in value-based care?
 - d. What can ONC do to address drug inventory transparency for prescribers and consumers?
- 3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
 - a. What standards gaps exist for the prescribing and management of:
 - i. specialty medications
 - ii. digital therapeutics
 - iii. gene therapies
- 4. Identify policy and technology needs and considerations for direct-to-consumer medication services.

Supporting Public Health

1. Public Health, Emergency Use Authorizations, and Prescribing Authorities


Short-term

- a. Identify critical standards and data needs for pharmacists and interested parties to participate in emergency use interventions.
- b. Are there actions ONC can take to enable data exchange in support of public health emergency use cases? For example, Test to Treat and COVID-19 treatment prescribing?

Long-term

a. Recommendations to better integrate pharmacy systems and data for public health surveillance, reporting and public health interventions.

Example of Fact Sheet for Healthcare Providers: Emergency Use Authorization



Supporting Clinical Pharmacy Services and Coordinated Care

2. Identify opportunities and recommendations to improve interoperability between pharmacy constituents (prescribers, pharmacists, pharmacy benefit managers, dispensers, payers, intermediaries, PDMPs, public health agencies, HIEs, third party service providers, consumers, etc.) for pharmacy-based clinical services and care coordination.

- a. How can ONC help facilitate adoption and use of standards to support data exchange for pharmacy-based clinical services?
- b. Which priority pharmacy-based clinical use cases should ONC focus on in the short-term and long-term?
- c. What technology gaps exist for pharmacists to participate in value-based care?
- d. What can ONC do to address drug inventory transparency for prescribers and consumers?



Emerging Therapeutics

- 3. Identify standards needs to support prescribing and management of emerging therapies including, but not limited to specialty medications, digital therapeutics, and gene therapies.
 - a. What standards gaps exist for the prescribing and management of:
 - i. specialty medications
 - ii. digital therapeutics
 - iii. gene therapies

Specialty prescribing mostly fax, portals, limited electronic routing and limited switch connectivity

No standard definition or terminologies for digital therapeutics, yet increasing in use

Expecting 10-20 FDA approvals of new gene therapies through 2025

Direct to Consumer Medication Services

4. Identify policy and technology needs and considerations for direct-to-consumer medication services





Pharmacy Interoperability and Emerging Therapeutics Task Force 2023 – Workplan

Key Meeting Dates	Agenda Items	
June 21	Task Force Kick-off Meeting	
August 17	Task Force Update to HITAC	
September 14	Task Force Update to HITAC	
October 19	Task Force Update to HITAC	
November 9	Task Force Delivers Final Recommendations to HITAC	

Regular Meeting Schedule: Wednesday 10:30 AM – 12 PM ET

HITAC Calendar: https://www.healthit.gov/topic/federal-advisory-committees/hitac-calendar

Please contact Mike Berry (<u>michael.berry@hhs.gov</u>) if additional HITAC members want to participate in this task force

Questions?